Phase 1 Study of Regorafenib in Combination With Vincristine and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors

被引：0
|
作者：
Casanova, M. [1 ]
Bautista, F. [2 ]
Campbell-Hewson, Q. [3 ]
Makin, G. [4 ,5 ]
Marshall, L. V. [6 ,7 ]
Verschuur, A. [8 ]
Canete Nieto, A. [9 ]
Corradini, N. [10 ]
Ploeger, B. [11 ]
Mueller, U. [12 ]
Zebger-Gong, H. [13 ]
Chung, J. [14 ]
Geoerger, B. [15 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Pediat Unit, Milan, Italy
[2] Hosp Infantil Univ Nino Jesus, Dept Paediat Oncol, Madrid, Spain
[3] Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Manchester, Manchester, Lancs, England
[5] Royal Manchester Childrens Hosp, Div Canc Sci, Sch Med Sci, Manchester, Lancs, England
[6] Royal Marsden Hosp, London, England
[7] Inst Canc Res, Paediat & Adolescent Drug Dev Team, London, England
[8] La Timone Childrens Hosp, Dept Pediat Oncol, Marseille, France
[9] Hosp Univ & Politecn La Fe, Unidad Oncol Pediat, Valencia, Spain
[10] Leon Berard Ctr, Hematol & Oncol Pediat Inst, Lyon, France
[11] Bayer AG, Clin Pharmacometr, Berlin, Germany
[12] ClinStat GmbH, Dept Stat, Cologne, Germany
[13] Bayer AG, Med Affairs & Pharmacovigilance, Berlin, Germany
[14] Bayer HealthCare Pharmaceut, Clin Dev Oncol, Whippany, NJ USA
[15] Univ Paris Saclay, Gustave Roussy Canc Ctr, Dept Pediat & Adolescent Oncol, Villejuif, France
来源：
PEDIATRIC BLOOD & CANCER | 2020年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0033
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [1] Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.
    Casanova, Michela
    Bautista, Francisco
    Hewson, Quentin Campbell
    Makin, Guy
    Marshall, Lynley V.
    Verschuur, Arnauld
    Canete, Adela
    Corradini, Nadege
    Ploeger, Bart
    Mueller, Udo
    Zebger-Gong, Hong
    Chung, John Woojune
    Geoerger, Birgit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
    Casanova, Michela
    Bautista, Francisco
    Campbell-Hewson, Quentin
    Makin, Guy
    Marshall, Lynley V.
    Verschuur, Arnauld C.
    Canete Nieto, Adela
    Corradini, Nadege
    Ploeger, Bart A.
    Brennan, Barbara J.
    Mueller, Udo
    Zebger-Gong, Hong
    Chung, John W.
    Geoerger, Birgit
    CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4341 - 4351
  • [3] Phase 1 Study of Oxaliplatin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
    McGregor, Lisa M.
    Spunt, Sheri L.
    Furman, Wayne L.
    Stewart, Clinton F.
    Schaiquevich, Paula
    Krailo, Mark D.
    Speights, RoseAnne
    Ivy, Percy
    Adamson, Peter C.
    Blaney, Susan M.
    CANCER, 2009, 115 (08) : 1765 - 1775
  • [4] Phase I Study of Bevacizumab Plus Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors
    Okada, Keiko
    Yamasaki, Kai
    Tanaka, Chika
    Fujisaki, Hiroyuki
    Osugi, Yuko
    Hara, Junichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1073 - 1079
  • [5] Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors
    Meany, Holly J.
    Widemann, Brigitte C.
    Hinds, Pamela S.
    Bagatell, Rochelle
    Shusterman, Suzanne
    Stern, Emily
    Jayaprakash, Nalini
    Peer, Cody J.
    Figg, William D.
    Hall, O. Morgan
    Sissung, Tristan M.
    Kim, Aerang
    Fox, Elizabeth
    London, Wendy B.
    Rodriguez-Galindo, Carlos
    Minturn, Jane E.
    Dome, Jeffrey S.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (11)
  • [6] Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
    Meany, Holly Jane
    Dome, Jeffrey
    Hinds, Pamela S.
    Bagatell, Rochelle
    Shusterman, Suzanne
    Widemann, Brigitte C.
    Stern, Emily
    London, Wendy B.
    Kim, AeRang
    Fox, Elizabeth
    Rodriguez-Galindo, Carlos
    Minturn, Jane E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] A Phase 1 Trial of Olaratumab as Monotherapy and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed/Refractory Solid Tumors
    Mascarenhas, L.
    Ogawa, C.
    Laetsch, T.
    Weigel, B.
    Bishop, M.
    Krystal, J.
    Levy, D.
    Mo, G.
    Wright, J.
    Dubois, S.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S433 - S434
  • [8] VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE TREATMENT FOR RECURRENT/PROGRESSIVE PEDIATRIC SOLID TUMORS
    Kebudi, R.
    Bay, S. Buyukkapu
    Cakir, F. B.
    Gorgun, O.
    Koc, B.
    Zulfikar, B.
    Agaoglu, F. Yaman
    Darendeliler, E.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S158 - S159
  • [9] Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.
    DuBois, Steven G.
    Weigel, Brenda
    Laetsch, Theodore Willis
    Macy, Margaret
    Levy, Donna Elise
    Mo, Gary
    Wright, Jennifer A.
    Mascarenhas, Leo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] A phase I study of cetuximab and irinotecan in pediatric patients (pts) with refractory solid tumors
    Trippett, T. M.
    Kuttesch, J.
    Herzog, C.
    Boklan, J.
    Bagatell, R.
    Hunger, S.
    Arceci, R.
    Lu, H.
    Langer, C.
    Gore, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345